ARTICLE | Clinical News
PF-06648671: Ph I data
January 27, 2017 4:28 AM UTC
A double-blind, placebo-controlled, Belgian Phase I trial in 92 healthy volunteers showed that single doses of 150 and 300 mg oral PF-06648671 and once-daily doses of 4-200 mg oral PF-06648671 for 14 ...
BCIQ Company Profiles
BCIQ Target Profiles